ANI Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $237,462 | $247,060 | $227,813 | $211,371 |
Gross Profit | 122,961 | 237,560 | 111,792 | 136,756 |
EBITDA | 59,625 | 76,931 | 61,159 | 39,244 |
EBIT | 38,706 | 54,318 | 38,527 | 15,963 |
Net Income | 29,492 | 27,490 | 24,134 | 8,549 |
Net Change In Cash | 237,462 | 247,060 | 227,813 | 211,371 |
Free Cash Flow | 52,301 | 6,507 | 37,892 | 68,903 |
Cash | 311,176 | 285,585 | 262,610 | 217,797 |
Basic Shares | 21,544 | 21,228 | 21,093 | 20,308 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $883,366 | $614,376 | $486,816 | $316,385 |
Gross Profit | 450,639 | 364,166 | 305,303 | 177,600 |
EBITDA | 207,268 | 63,121 | 106,603 | 25,040 |
EBIT | 115,851 | -4,610 | 46,812 | -34,613 |
Net Income | 78,337 | -18,522 | 18,779 | -47,896 |
Net Change In Cash | 883,366 | 614,376 | 486,816 | 316,385 |
Cost of Revenue | -52,067 | |||
Free Cash Flow | 171,390 | 47,064 | 100,448 | -47,658 |
Cash | 285,585 | 144,861 | 221,121 | 48,228 |
Basic Shares | 21,228 | 19,318 | 18,194 | 16,260 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $2.05 |
2025-12-31 | $2.33 |
2025-09-30 | $2.04 |
2025-06-30 | $0.36 |